Potent analgesic and anti-inflammatory activities of 1-furan-2-yl-3- pyridin-2-yl-propenone with gastric ulcer sparing effect

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 2, 2006, Pages 361-364

  Lee, Eung Seok ^a   Park, Byung Chul ^a   Paek, Seung Hwan ^a   Lee, Yoon Seok ^a   Basnet, Arjun ^a   Jin, Da Qing ^a   Choi, Han Gon ^a   Yong, Chul Soon ^a   Kim, Jung Ae ^a  

^a Yeungnam University   (South Korea)

Author keywords

1 furan 2 yl 3 pyridin 2 yl propenone; Acetylsalicylic acid; Analgesic; Anti inflammatory; Indomethacin; Ulcerogenic

Indexed keywords

1 FURAN 2 YL 3 PYRIDIN 2 YLPROPENONE; ACETIC ACID; ACETYLSALICYLIC ACID; CARRAGEENAN; FURAN DERIVATIVE; INDOMETACIN; LIPOXYGENASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SELECTIVITY; INFLAMMATION; MOUSE; NONHUMAN; PAIN; PAW EDEMA; RAT; STOMACH HEMORRHAGE; STOMACH MUCOSA; STOMACH ULCER; WRITHING TEST;

EID: 32044431662     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.361     Document Type: Article

References (19)

1. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Isakson P., Adv. Exp. Med. Biol., 400A, 167-170 (1997).
2. Prescott S. M., Fitzpatrick F. A., Biochim. Biophys. Acta, 1470, 69-78 (2000).
3. Wolfe M. M., Lichtenstein D. R., Singh G., N. Engl. J. Med., 340, 1888-1899 (1999).
4. Burnier M., Expert Opin. Drug Saf., 4, 491-499 (2005).
5. Wong D., Wang M., Cheng Y., Fitzgerald G. A., Curr. Opin. Pharmacol., 5, 204-210 (2005).
6. Rudic R. D., Brinster D., Cheng Y., Fries S., Song W. L., Austin S., Coffman T. M., FitzGerald G. A., Circ. Res., 96, 1240-1247 (2005).
7. Moncada S., Vane J. R., Bull. Eur. Physiopathol. Respir., 17, 687-701 (1981).
8. McAdam B. F., Catella-Lawson F., Mardini I. A., Kapoor S., Lawson J. A., FitzGerald G. A., Proc. Natl. Acad. Sci. U.S.A., 96, 272-277 (1999).
9. Bolten W. W., Ann. Rheum. Dis., [Epub ahead of print] (2005)
10. Rainsford K. D., Agents Actions, 39, 24-26 (1993).
11. Jahng Y., Zhao L. X., Moon Y. S., Basnet A., Kim E. K., Chang H. W., Ju H. K., Jeong T. C., Lee E. S., Bioorg. Med. Chem. Lett., 14, 2559-2562 (2004).
12. Lee E. S., Ju H. K., Moon T. C., Lee E., Jahng Y., Lee S. H., Son J. K., Baek S. H., Chang H. W., Biol. Pharm. Bull., 27, 617-620 (2004).
13. Ferreira S. H., J. Pharm. Pharmacol., 31, 648 (1979).
14. Vinegar R., Schreiber W., Hugo R., J. Pharmacol. Exp. Ther., 166, 96-103 (1969).
15. Gyomber E., Vattay P., Szabo S., Rainsford K. D., J. Gastroenterol. Hepatol., 11, 922-927 (1996).
16. Ligumsky M., Sestieri M., Karmeli F., Zimmerman J., Okon E., Rachmilewitz D., Gasteroenterology, 98, 1245-1249 (1990).
17. Deraedt R., Jouquey S., Delevallee F., Flahaut M., Eur. J. Pharmacol., 61, 17-24 (1980).
18. Funk C. D., Science, 294, 1871-1875 (2001).
19. Singh V. P., Patil C. S., Kulkarni S. K., Pharmacol. Biochem. Behav., 81, 433-439 (2005).